{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,24]],"date-time":"2026-09-24T17:32:41Z","timestamp":1790271161015,"version":"4.1.0"},"reference-count":17,"publisher":"Wiley","issue":"4","license":[{"start":{"date-parts":[[2006,7,20]],"date-time":"2006-07-20T00:00:00Z","timestamp":1153353600000},"content-version":"vor","delay-in-days":4128,"URL":"http:\/\/onlinelibrary.wiley.com\/termsAndConditions#vor"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Med. Pediatr. Oncol."],"published-print":{"date-parts":[[1995,4]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:p>Levamisole is an immunomodulatory agent which is used in the adjuvant therapy of certain malignancies. Agranulocytosis is the most commonly reported hematologic side effect associated with this drug. We report here a patient who developed thrombocytopenia nearly 2 years after starting adjuvant levamisole therapy for malignant melanoma. In this case, thrombocytopenia was shown to be levamisole\u2010related by re\u2010challenge with the drug. Levamisole\u2010induced thrombocytopenia (LIT) has been rarely diagnosed, but may be seen more frequently as increasing numbers of patients receive adjuvant therapy for colon cancer and melanoma. \u00a9 1995 Wi1ey\u2010Liss Inc.<\/jats:p>","DOI":"10.1002\/mpo.2950240409","type":"journal-article","created":{"date-parts":[[2007,2,20]],"date-time":"2007-02-20T19:24:21Z","timestamp":1171999461000},"page":"262-264","source":"Crossref","is-referenced-by-count":13,"title":["Reversible thrombocytopenia with levamisole"],"prefix":"10.1002","volume":"24","author":[{"given":"Eric W.","family":"Winquist","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Norman J.","family":"Lassam","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"311","published-online":{"date-parts":[[2006,7,20]]},"reference":[{"key":"e_1_2_1_2_2","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.1989.7.10.1447"},{"key":"e_1_2_1_3_2","doi-asserted-by":"publisher","DOI":"10.1056\/NEJM199002083220602"},{"issue":"5","key":"e_1_2_1_4_2","doi-asserted-by":"crossref","first-page":"729","DOI":"10.1200\/JCO.1991.9.5.729","article-title":"Improved survival in patients with poor\u2010prognosis malignant melanoma treated with adjuvant levamisole: a phase III study by the National Cancer Institute of Canada Clinical Trials Group","volume":"9","author":"Quirt IC","year":"1991","journal-title":"J Clin Oncol"},{"issue":"11","key":"e_1_2_1_5_2","doi-asserted-by":"crossref","first-page":"2052","DOI":"10.1200\/JCO.1991.9.11.2052","article-title":"Levamisole: known effects on the immune system, clinical results, and future applications to the treatment of cancer","volume":"9","author":"Stevenson HC","year":"1991","journal-title":"J Clin Oncol"},{"key":"e_1_2_1_6_2","doi-asserted-by":"publisher","DOI":"10.1056\/NEJM197308162890707"},{"issue":"11","key":"e_1_2_1_7_2","first-page":"1721","article-title":"Adverse reactions to levamisole","volume":"62","author":"Symoens J","year":"1978","journal-title":"Cancer Treat Rep"},{"key":"e_1_2_1_8_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(77)92386-8"},{"key":"e_1_2_1_9_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(77)90082-4"},{"key":"e_1_2_1_10_2","doi-asserted-by":"publisher","DOI":"10.1136\/bmj.2.6086.555-a"},{"issue":"11","key":"e_1_2_1_11_2","first-page":"633","article-title":"Treatment of rheumatic polyarthritis in 26 patients","volume":"44","author":"d'Anglejan G","year":"1977","journal-title":"Rev Rhum Mal Osteoartic"},{"key":"e_1_2_1_12_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0022-3476(78)80530-7"},{"issue":"1","key":"e_1_2_1_13_2","first-page":"104","article-title":"Levamisole induced granulocytopenia and thrombocytopenia in a case of Crohn's colitis","volume":"3","author":"Sategna\u2010Guidetti C","year":"1979","journal-title":"Gastroenterol Clin Biol"},{"issue":"3","key":"e_1_2_1_14_2","first-page":"171","article-title":"Levamisole\u2010induced agranulocytosis and thrombocytopenia [Dan]","volume":"142","author":"Nielsen JL","year":"1980","journal-title":"Ugeskr Laeger"},{"key":"e_1_2_1_15_2","doi-asserted-by":"publisher","DOI":"10.1097\/00007611-198207000-00041"},{"key":"e_1_2_1_16_2","doi-asserted-by":"publisher","DOI":"10.1159\/000206608"},{"key":"e_1_2_1_17_2","doi-asserted-by":"publisher","DOI":"10.1002\/ajh.2830090205"},{"key":"e_1_2_1_18_2","doi-asserted-by":"publisher","DOI":"10.1016\/0360-3016(88)90229-5"}],"container-title":["Medical and Pediatric Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1002%2Fmpo.2950240409","content-type":"unspecified","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1002\/mpo.2950240409","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,10,25]],"date-time":"2023-10-25T17:48:19Z","timestamp":1698256099000},"score":1,"resource":{"primary":{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/10.1002\/mpo.2950240409"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[1995,4]]},"references-count":17,"journal-issue":{"issue":"4","published-print":{"date-parts":[[1995,4]]}},"alternative-id":["10.1002\/mpo.2950240409"],"URL":"https:\/\/doi.org\/10.1002\/mpo.2950240409","archive":["Portico"],"relation":{},"ISSN":["0098-1532","1096-911X"],"issn-type":[{"value":"0098-1532","type":"print"},{"value":"1096-911X","type":"electronic"}],"subject":[],"published":{"date-parts":[[1995,4]]}}}